



# ANUH PHARMA LTD.

3-A, Shivsagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, MUMBAI - 400 018. INDIA  
Tel. : 91-22-6622 7575 • Fax : 91-22-6622 7600 / 7500  
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

14<sup>th</sup> November, 2018

To,  
The Manager (Listing)  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Fort, Mumbai - 400 001

**Sub: Submission of Unaudited Financial Results along with Limited Review Report for the quarter & half year ended 30<sup>th</sup> September, 2018**

**Ref: Scrip Code No. 506260**

Dear Sir,

Pursuant to the provisions of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following:

1. Unaudited Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2018; and
2. Limited Review Report for the quarter ended 30<sup>th</sup> September, 2018.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully,  
For **Anuh Pharma Limited**

*A-S. Ambrale*  
**Ashwini Ambrale**  
**Company Secretary & Compliance Officer**  
**(Membership No.: A32456)**



**Encl: As above**



We Serve Since 1932

Factory : E-17/3 & 17/4, M.I.D.C., Tarapur. BOISAR, Dist. Palghar - 401 506. INDIA Tel.: 74100 55574 / 74100 55575

# ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586

Regd. Office : 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018


Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

## UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2018

(Rs. in Lakhs)

Sr. No.	Particulars	3 months ended 30/09/2018	3 months ended 30/06/2018	3 months ended 30/09/2017	6 months ended 30/09/2018	6 months ended 30/09/2017	12 months ended 31/03/2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I.	Revenue from operations (Refer note. 3)	8,736.72	8,024.87	5,530.79	16,761.59	10,950.40	24,123.59
II.	Other income	147.23	114.74	272.57	261.97	514.99	738.98
III.	<b>Total Revenue (I + II)</b>	<b>8,883.95</b>	<b>8,139.61</b>	<b>5,803.36</b>	<b>17,023.56</b>	<b>11,465.39</b>	<b>24,862.57</b>
IV.	Expenses:						
	Cost of materials consumed	6,381.10	6,414.39	4,364.43	12,795.49	8,236.61	18,372.29
	Purchases of Stock-in-Trade	-	-	-	-	-	34.62
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	46.96	(270.25)	(85.37)	(223.29)	(74.99)	(327.74)
	Employee benefits expense	273.79	237.88	222.37	511.67	421.66	900.11
	Finance costs	1.66	0.77	0.12	2.43	0.15	4.05
	Depreciation and amortization expense	36.90	35.22	45.13	72.12	86.63	183.15
	Excise duty	-	-	-	-	315.92	315.92
	Other expenses	1,188.18	952.26	832.05	2,140.44	1,287.17	3,038.46
	<b>Total expenses (IV)</b>	<b>7,928.59</b>	<b>7,370.27</b>	<b>5,378.73</b>	<b>15,298.86</b>	<b>10,273.15</b>	<b>22,520.86</b>
V.	<b>Profit / (Loss) before exceptional and items and tax (III - IV)</b>	<b>955.36</b>	<b>769.34</b>	<b>424.63</b>	<b>1,724.70</b>	<b>1,192.24</b>	<b>2,341.71</b>
VI.	Exceptional items	-	-	-	-	-	-
VII.	<b>Profit / (Loss) before tax (V - VI)</b>	<b>955.36</b>	<b>769.34</b>	<b>424.63</b>	<b>1,724.70</b>	<b>1,192.24</b>	<b>2,341.71</b>
VIII.	Tax expense:						
	(1) Current tax	250.80	212.80	174.00	463.60	316.00	686.00
	(2) Deferred tax	8.95	(13.19)	43.92	(4.24)	43.92	4.47
		<b>259.75</b>	<b>199.61</b>	<b>217.92</b>	<b>459.36</b>	<b>359.92</b>	<b>690.47</b>
IX.	<b>Profit/(Loss) after Tax (VII-VIII)</b>	<b>695.61</b>	<b>569.73</b>	<b>206.71</b>	<b>1,265.34</b>	<b>832.32</b>	<b>1,651.24</b>
X.	Other Comprehensive Income (net of Tax)						
	(i) Items that will not be reclassified to profit or loss	0.20	(0.03)	2.00	0.17	8.01	5.18
	(ii) Items that will be reclassified to profit or loss	0	-	-	-	-	-
	<b>Total Other Comprehensive Income (net of Tax)</b>	<b>0.20</b>	<b>(0.03)</b>	<b>2.00</b>	<b>0.17</b>	<b>8.01</b>	<b>5.18</b>
XI.	<b>Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)</b>	<b>695.81</b>	<b>569.70</b>	<b>208.71</b>	<b>1,265.51</b>	<b>840.33</b>	<b>1,656.42</b>
	Paid up Equity Share Capital (Face value ₹ 5/- each)	1,252.80	1,252.80	1,252.80	1,252.80	1,252.80	1,252.80
	Other Equity (excluding revaluation reserves)						13,708.72
XII.	Earnings per equity share (Non annualised) (In Rs.)						
	(1) Basic	2.78	2.27	0.82	5.05	3.32	6.59
	(2) Diluted	2.78	2.27	0.82	5.05	3.32	6.59

See accompanying notes to the financial results



## Note-1

## Statement of Assets and Liabilities

(Rs. in Lakhs)

PARTICULARS		As at September 30, 2018	As at March 31, 2018
<b>I</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current Assets</b>		
	(a) Fixed Assets		
	(i) Property, Plant and equipment	1,586.79	1,633.00
	(ii) Capital work-in-progress	1,123.43	591.83
	(iii) Intangible Assets	36.32	37.06
		2,746.54	2,261.89
	(b) Financial Assets		
	(i) Investments	2,993.36	3,069.57
	(ii) Loans and Advances	-	-
	(iii) Other Financial Assets	67.30	55.76
	(c) Deferred Tax Assets (Net)	118.64	114.48
	<b>Total Non-Current Assets</b>	5,925.84	5,501.70
<b>2</b>	<b>Current Assets</b>		
	(a) Inventories	6,258.10	3,190.40
	(b) Financial Assets		
	(i) Investments	1,127.42	3,556.50
	(ii) Trade receivables	8,990.96	7,092.31
	(iii) Cash and cash equivalents	914.11	379.91
	(iv) Other Bank balances	420.42	420.40
	(v) Loans and Advances	37.17	43.04
	(vi) Other financial assets	113.50	213.30
	(c) Other current assets	675.90	521.69
	<b>Total Current Assets</b>	18,537.58	15,417.55
	<b>TOTAL ASSETS</b>	24,463.42	20,919.25
<b>I</b>	<b>EQUITY AND LIABILITIES</b>		
	<b>Equity</b>		
	(i) Equity Share Capital	1,252.80	1,252.80
	(ii) Other Equity	14,143.58	13,708.72
	<b>TOTAL EQUITY</b>	15,396.38	14,961.52
	<b>Liabilities</b>		
<b>1</b>	<b>NON-CURRENT LIABILITIES</b>		
	Provisions	95.60	94.83
	<b>TOTAL NON-CURRENT LIABILITIES</b>	95.60	94.83
<b>2</b>	<b>CURRENT LIABILITIES</b>		
	(a) Financial Liabilities		
	(i) Borrowings	296.62	244.38
	(ii) Trade Payables	7,742.44	5,198.38
	(iii) Other financial liabilities	758.24	246.36
	(b) Other current liabilities	24.80	44.21
	(c) Provisions	17.11	19.65
	(d) Current Tax Liabilities(Net)	132.23	109.92
	<b>TOTAL CURRENT LIABILITIES</b>	8,971.44	5,862.90
	<b>TOTAL EQUITY AND LIABILITIES</b>	24,463.42	20,919.25



*Prasanna*

2. The results of the quarter and half year ended September 30, 2018 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 14, 2018. They have been subjected to limited review by the Statutory Auditor.

3. Post implementation of Goods & Service Tax (GST) w.e.f. July 01, 2017, revenue from operations is disclosed net off GST, revenue from operations for the earlier periods included excise duty which is now subsumed in GST. Revenue from operations for the half year ended September 30, 2017 and the year ended March 31, 2018 includes excise duty upto June 30, 2017. Hence, revenue from operations for the half year ended September 30, 2018 is not comparable to those of previous periods reported.


4. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided.

5. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.

For Anuh Pharma Limited

*Bipin N. Shah*

**Bipin N. Shah**  
**Managing Director**  
**(DIN: 00083244)**



Place : Mumbai

Dated : November 14, 2018

**REVIEW REPORT TO THE BOARD OF DIRECTORS OF**  
**ANUH PHARMA LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Anuh Pharma Limited** ("the Company") for the quarter and half year ended 30<sup>th</sup> September, 2018 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

PLACE: Mumbai  
DATE: 14<sup>th</sup> November, 2018



For **JAYANTILAL THAKKAR & CO.**  
**CHARTERED ACCOUNTANTS**  
**(FIRM REG. NO. 104133W)**

*V. A. Merchant*

**VIRAL A. MERCHANT**  
**PARTNER**  
**MEMBERSHIP NO. 116279**